Clinical trial / 2017
Once-weekly semaglutide reduced daily ad libitum energy intake by 24% and reduced body weight by 5.0 kg over 12 weeks in subjects with obesity.
In a randomised, double-blind, placebo-controlled crossover trial, 30 subjects with obesity received 12 weeks of once-weekly subcutaneous semaglutide (dose-escalated to 1.0 mg) or placebo. Semaglutide led to a lower ad libitum energy intake during lunch (-1255 kJ; P < .0001), the evening meal (P = .0401), and snacks (P = .0034), producing a 24% reduction in total daily ad libitum energy intake (-3036 kJ; P < .0001). Semaglutide also improved fasting appetite suppression scores, reduced hunger, cravings, and preference for high-fat foods, and reduced mean body weight by 5.0 kg predominantly from fat mass, with no difference in lean-mass-adjusted resting metabolic rate.
- Study type
- Randomised, double-blind, placebo-controlled crossover trial
- Who was studied
- 30 subjects with obesity
- What was measured
- Ad libitum energy intake, appetite ratings, control of eating, food preference, resting metabolic rate, body weight, and body composition
THE PAPER
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Diabetes Obes Metab, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.